英语翻译"Although the company was well capitalized,we felt that additional resources would allow us to more aggressively execute our hiring plan for 2008," commented Tillman Gerngross,Ph.D.,Chief Executive Officer of Adimab."We have also accelera
来源:学生作业帮助网 编辑:作业帮 时间:2024/11/06 07:33:58
英语翻译"Although the company was well capitalized,we felt that additional resources would allow us to more aggressively execute our hiring plan for 2008," commented Tillman Gerngross,Ph.D.,Chief Executive Officer of Adimab."We have also accelera
英语翻译
"Although the company was well capitalized,we felt that additional resources would allow us to more aggressively execute our
hiring plan for 2008," commented Tillman Gerngross,Ph.D.,Chief Executive Officer of Adimab."We have also accelerated our
high throughput antibody expression and fermentation program,which is now expected to come on line in the second quarter of
this year.Upon completion,we will be able to go from antigen to a panel of fully human antibodies in less than ninety
days."
"We have seen many antibody discovery platforms and felt that Adimab has the most compelling and seamless offering," said
Michael Ross,Ph.D.,Managing Partner,SV Life Sciences."Adimab has assembled a great team,has a thorough understanding of
the IP,has made excellent progress on its technology,and has generated strong interest from several partners."
"Tillman runs a lean team,but they consistently set high expectations and then over-deliver," says Terry McGuire,Managing
General Partner of Polaris Ventures."The speed at which Adimab assembled a word class antibody discovery team and
implemented its business strategy was impressive."
在线翻译的不要发到这里
我有50分
英语翻译"Although the company was well capitalized,we felt that additional resources would allow us to more aggressively execute our hiring plan for 2008," commented Tillman Gerngross,Ph.D.,Chief Executive Officer of Adimab."We have also accelera
“尽管公司资本雄厚,我们仍感到更多资源能让我们更激进地执行我们2008年的招聘计划,”Adimab公司首席执行官Tillman Gerngross博士评论说.“我们还加快了高产抗体和发酵项目的进度,现预期将于今年第二季度上线.项目完成后,我们将能够在90日内从抗原生产转向一系列完全人体抗体的生产.”
“我们见过许多抗体发现平台,并感到Adimab的产品是最强的,也是最全的,” SV生命科学公司经理合伙人Michael Ross博士说.“Adimab有强大的团队,对知识产权有透彻了解,并且技术先进,使多个合伙人产生了强烈的兴趣.”
“Tillman管理团队的规模不大,但他们不断提高人们的期望值并超越它,” Polaris风险投资公司的总经理合伙人Terry McGuire说.“Adimab组建一流抗体发现团队并实施其商业策略的速度令人印象深刻.”